{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:03:44Z","timestamp":1791180224332,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2008,2,16]],"date-time":"2008-02-16T00:00:00Z","timestamp":1203120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,2,16]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Clinical investigations of recombinant human acid \u03b1-glucosidase for the treatment of Pompe disease often reveal the appearance of therapy-specific antibodies. These antibodies could potentially interfere with recombinant human acid \u03b1-glucosidase efficacy and induce immunological consequences. Several immunosuppressive agents, including methotrexate, mycophenolate mofetil and cyclosporin A with azathioprine, were evaluated for their potential to induce immune tolerance to recombinant human acid \u03b1-glucosidase. Methotrexate was the only agent that reduced recombinant human acid \u03b1-glucosidase-specific antibody responses in acid \u03b1-glucosidase knock-out mice. A 3-week, low-dose methotrexate regimen controlled recombinant human acid \u03b1-glucosidase-specific antibody levels throughout 8\u2003months of weekly recombinant human acid \u03b1-glucosidase treatment. The success of this methotrexate regimen appears to require methotrexate administration within the first 24\u2003h of recombinant human acid \u03b1-glucosidase treatment. In an attempt to understand the benefit of methotrexate within the first day of recombinant human acid \u03b1-glucosidase administration, the immune response 24\u2003h following intravenous recombinant human acid \u03b1-glucosidase treatment was investigated. A consistent expansion of peritoneal B1 B cells was observed. Control over this B1 B cell response may be part of the complex mechanism of action of methotrexate-induced immune tolerance.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2008.03602.x","type":"journal-article","created":{"date-parts":[[2010,7,26]],"date-time":"2010-07-26T18:52:34Z","timestamp":1280170354000},"page":"138-146","source":"Crossref","is-referenced-by-count":75,"title":["Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model"],"prefix":"10.1093","volume":"152","author":[{"given":"A","family":"Joseph","sequence":"first","affiliation":[{"name":"Immunology Laboratory, Biologics R&D, Genzyme Corporation, Framingham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Munroe","sequence":"additional","affiliation":[{"name":"Immunology Laboratory, Biologics R&D, Genzyme Corporation, Framingham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Housman","sequence":"additional","affiliation":[{"name":"Immunology Laboratory, Biologics R&D, Genzyme Corporation, Framingham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Garman","sequence":"additional","affiliation":[{"name":"Immunology Laboratory, Biologics R&D, Genzyme Corporation, Framingham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Richards","sequence":"additional","affiliation":[{"name":"Immunology Laboratory, Biologics R&D, Genzyme Corporation, Framingham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2008,2,25]]},"reference":[{"key":"2022010405171288000_b1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1520-6017(200101)90:1<1::AID-JPS1>3.0.CO;2-K","article-title":"Human immune response to recombinant human proteins","volume":"90","author":"Porter","year":"2001","journal-title":"J Pharm Sci"},{"key":"2022010405171288000_b2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/1389201023378175","article-title":"Immune responses to therapeutic proteins in humans\u2003\u2212\u2003clinical significance, assessment and prediction","volume":"3","author":"Koren","year":"2002","journal-title":"Curr Pharm Biotechnol"},{"key":"2022010405171288000_b3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molmed.2003.08.004","article-title":"Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder","volume":"9","author":"Brooks","year":"2003","journal-title":"Trends Mol Med"},{"key":"2022010405171288000_b4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1529-1049(02)00049-1","article-title":"Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders","volume":"2","author":"Richards","year":"2002","journal-title":"Clin Appl Immunol Rev"},{"key":"2022010405171288000_b5","first-page":"2443","volume-title":"The metabolic and molecular basis of inherited disease","author":"Hirschhorn","year":"1995","edition":"7th"},{"key":"2022010405171288000_b6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid \u03b1-glucosidase. Major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"2022010405171288000_b7","first-page":"132","article-title":"Recombinant human acid \u03b1-glucosidase enzyme therapy for infantile glycogen storage disease type II. Results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet Med"},{"key":"2022010405171288000_b8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1073\/pnas.0305480101","article-title":"Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I","volume":"101","author":"Kakkis","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022010405171288000_b9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00007890-199701150-00008","article-title":"Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection","volume":"63","author":"Halloran","year":"1997","journal-title":"Transplantation"},{"key":"2022010405171288000_b10","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2249.2004.02567.x","article-title":"Methotrexate reduces antibody responses to recombinant human \u03b1-galactosidase A therapy in a mouse model of Fabry disease","volume":"137","author":"Garman","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"2022010405171288000_b11","doi-asserted-by":"crossref","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","article-title":"Targeted disruption of the acid \u03b1-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II","volume":"273","author":"Raben","year":"1998","journal-title":"J Biol Chem"},{"key":"2022010405171288000_b12","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood.V93.6.2081.406k07_2081_2088","article-title":"Immunosurveillance of Alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration","volume":"93","author":"Rosenberg","year":"1999","journal-title":"Blood"},{"key":"2022010405171288000_b13","first-page":"792","article-title":"Loss of interferon antibodies during prolonged continuous interferon-\u03b1 2a therapy in hairy cell leukemia","volume":"77","author":"Steis","year":"1991","journal-title":"Blood"},{"key":"2022010405171288000_b14","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(03)13311-9","article-title":"Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I","volume":"361","author":"Kakavanos","year":"2003","journal-title":"Lancet"},{"key":"2022010405171288000_b15","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.20278","article-title":"Toward a better understanding of methotrexate","volume":"50","author":"Kremer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2022010405171288000_b16","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1046\/j.1365-2249.1999.00901.x","article-title":"Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr\/lpr mice","volume":"116","author":"Jonsson","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"2022010405171288000_b17","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI16432","article-title":"CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes","volume":"111","author":"Tiede","year":"2003","journal-title":"J Clin Invest"},{"key":"2022010405171288000_b18","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1006\/clin.1996.0140","article-title":"The mechanism of action of cyclosporin A and FK506","volume":"80","author":"Ho","year":"1996","journal-title":"Clin Immunol Immunopathol"},{"key":"2022010405171288000_b19","first-page":"235","article-title":"Regulation of B-cell commitment to plasma cells or to memory B cells","volume":"9","author":"Liu","year":"1997","journal-title":"Immunology"},{"key":"2022010405171288000_b20","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/352803a0","article-title":"Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporine A","volume":"352","author":"Flanagan","year":"1991","journal-title":"Nature"},{"key":"2022010405171288000_b21","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1126\/science.2595372","article-title":"Cyclosporine A specifically inhibits function of nuclear proteins involved in T-cell activation","volume":"246","author":"Emmel","year":"1989","journal-title":"Science"},{"key":"2022010405171288000_b22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF02220605","article-title":"The clinical pharmacology of 6-mercaptopurine","volume":"43","author":"Lennard","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"2022010405171288000_b23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Myclophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"2022010405171288000_b24","volume-title":"Martindale: The Complete Drug Reference","author":"Sweetman","year":"2006"},{"key":"2022010405171288000_b25","doi-asserted-by":"crossref","first-page":"7170","DOI":"10.4049\/jimmunol.175.11.7170","article-title":"An hour after immunization peritoneal B-1 cells are activated to migrate to lymphoid organs where within 1 day they produce IgM antibodies that initiate elicitation of contact sensitivity","volume":"175","author":"Itakura","year":"2005","journal-title":"J Immunol"},{"key":"2022010405171288000_b26","first-page":"9","article-title":"Effect of low dose methotrexate on neutrophil chemotaxis induced by leukotriene B4 and complement C5a","volume":"14","author":"Suarez","year":"1987","journal-title":"J Rheumatol"},{"key":"2022010405171288000_b27","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/anr.1780320403","article-title":"The effects of methotrexate on the production and activity of interleukin-1","volume":"32","author":"Segal","year":"1989","journal-title":"Arthritis Rheum"},{"key":"2022010405171288000_b28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00296-002-0267-y","article-title":"Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis","volume":"23","author":"Aggarwal","year":"2003","journal-title":"Rheumatol Int"},{"key":"2022010405171288000_b29","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/rheumatology\/keg323","article-title":"Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis","volume":"42","author":"Gerards","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"2022010405171288000_b30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/0003-4819-103-4-489","article-title":"Weekly pulse methotrexate in rheumatoid arthritis","volume":"103","author":"Anderson","year":"1985","journal-title":"Ann Intern Med"},{"key":"2022010405171288000_b31","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/art.1780330706","article-title":"The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation of methyl donors and spermidine","volume":"33","author":"Nesher","year":"1990","journal-title":"Arthritis Rheum"},{"key":"2022010405171288000_b32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/rheumatology\/kei193","article-title":"Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis","volume":"45","author":"Kapetanovic","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"2022010405171288000_b33","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1172\/JCI116884","article-title":"The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation","volume":"92","author":"Cronstein","year":"1993","journal-title":"J Clin Invest"},{"key":"2022010405171288000_b34","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/rheumatology\/39.5.533","article-title":"Methotrexate as a preferential cyclooxygenase 2 inhibitor in whole blood of patients with rheumatoid arthritis","volume":"39","author":"Mello","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"2022010405171288000_b35","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4049\/jimmunol.141.2.410","article-title":"Suppression of B cell function by methotrexate and trimetrexate","volume":"141","author":"Rosenthal","year":"1998","journal-title":"J Immunol"},{"key":"2022010405171288000_b36","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1172\/JCI2676","article-title":"Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells","volume":"102","author":"Genestier","year":"1998","journal-title":"J Clin Invest"},{"key":"2022010405171288000_b37","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/S0041-1345(98)00648-4","article-title":"Activation-induced lymphocyte apoptosis induced by methotrexate","volume":"30","author":"Paillot","year":"1998","journal-title":"Transplant Proc"},{"key":"2022010405171288000_b38","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1084\/jem.20041236","article-title":"Imaging the single cell dynamics of CD4+ T cell activation by dendritic cells in lymph nodes","volume":"200","author":"Miller","year":"2004","journal-title":"J Exp Med"},{"key":"2022010405171288000_b39","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/mpo.2950240303","article-title":"Pharmacokinetics of HD-MTX in infants, children and adolescents with non-b acute lymphoblastic leukemia","volume":"24","author":"Donelli","year":"1995","journal-title":"Med Ped Oncol"},{"key":"2022010405171288000_b40","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1542\/peds.2003-0988-L","article-title":"Nephrotic syndrome complicating \u03b1-glucosidase replacement therapy for Pompe disease","volume":"114","author":"Hunley","year":"2004","journal-title":"Pediatrics"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2008.03602.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2008.03602.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/152\/1\/138\/42045448\/j.1365-2249.2008.03602.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/152\/1\/138\/42045448\/j.1365-2249.2008.03602.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T09:57:13Z","timestamp":1685699833000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/152\/1\/138\/6457534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,16]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2008,2,25]]},"published-print":{"date-parts":[[2008,2,16]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2008.03602.x","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,4]]},"published":{"date-parts":[[2008,2,16]]}}}